Prevalence of high inflammatory risk (hsCRP ≥2 mg/L) in European patients with atherosclerotic cardiovascular disease with/without chronic kidney disease: sub-analysis of the global POSEIDON study

31 August 2026 (08:45 - 08:55)
Organised by: Logo
Congress Presentation Part of: Modulation of risk and outcomes in peripheral artery disease Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology